CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer

PURPOSE: In hormone receptor–positive (HR+)/HER2− metastatic breast cancer (MBC), it is imperative to identify patients who respond poorly to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and to discover therapeutic targets to reverse this resistance. Non-luminal breast cancer subtype and high le...

Descripción completa

Detalles Bibliográficos
Autores principales: Guerrero-Zotano, Ángel, Belli, Stefania, Zielinski, Christoph, Gil-Gil, Miguel, Fernandez-Serra, Antonio, Ruiz-Borrego, Manuel, Ciruelos Gil, Eva Maria, Pascual, Javier, Muñoz-Mateu, Montserrat, Bermejo, Begoña, Margeli Vila, Mireia, Antón, Antonio, Murillo, Laura, Nissenbaum, Bella, Liu, Yuan, Herranz, Jesús, Fernández-García, Daniel, Caballero, Rosalía, López-Guerrero, José Antonio, Bianco, Roberto, Formisano, Luigi, Turner, Nicholas, Martín, Miguel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Precision Medicine and Imaging
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10102847/
https://www.ncbi.nlm.nih.gov/pubmed/36749874
http://dx.doi.org/10.1158/1078-0432.CCR-22-2206

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10102847/
https://www.ncbi.nlm.nih.gov/pubmed/36749874
http://dx.doi.org/10.1158/1078-0432.CCR-22-2206

Ejemplares similares